Several hedge funds recently changed their investments in Madrigal Pharmaceuticals. First Horizon Advisors Inc. increased its stake by 1,633.3% in Q2, owning 104 shares worth $29,000 after acquiring 98 more shares. EntryPoint Capital LLC bought shares worth around $41,000 in Q1. Signaturefd LLC raised its stake by 36.8% in Q2, owning 145 shares valued at $41,000 after buying 39 additional shares. Quest Partners LLC raised its position by 5,225.0% in Q2, now holding 213 shares worth $60,000. BNP Paribas also purchased shares in Q1, valued at about $68,000. Overall, institutional investors control 98.50% of the company’s stock.
Madrigal Pharmaceuticals Stock Performance
MDGL stock opened at $214.44 on Friday. The stock has a 50-day average of $232.19 and a 200-day average of $243.82. The 52-week range is $119.76 – $299.98. Key ratios include a debt-to-equity ratio of 0.14, a current ratio of 8.72, and a quick ratio of 8.67. The market cap is $4.66 billion, with a PE ratio of -8.41 and a beta of -0.44.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) reported earnings on August 7, with an EPS of ($7.10), exceeding estimates of ($7.55) by $0.45. Revenue came in at $14.64 million, well above the $4.25 million expected, up 146,280% year-over-year. Analysts predict an EPS of -27.47 for the current year.
Insider Buying and Selling
CEO William John Sibold sold 6,363 shares on September 9 for $1,551,490.29, retaining 55,887 shares valued at about $13.63 million. This sale was a negligible decrease in his position, as disclosed to the SEC. Corporate insiders own 22.80% of the company.
Analyst Upgrades and Downgrades
Analysts have mixed views on the stock. StockNews.com downgraded it to “sell” on October 12. Evercore ISI lowered its target from $405 to $360 but maintains an “outperform” rating. JMP Securities increased their price target to $385 with a “market outperform” rating. Cantor Fitzgerald kept a “neutral” rating, while Citigroup lowered its target from $382 to $371, assigning a “buy” rating. Currently, two analysts rate it “sell,” two “hold,” and ten “buy,” giving it an average “Moderate Buy” rating with a target price of $343.83.
Get Our Latest Stock Report on Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Profile
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for non-alcoholic steatohepatitis (NASH), with its lead product, resmetirom, currently in Phase 3 trials.
Featured Articles
- Five stocks we like better than Madrigal Pharmaceuticals
- 3 Small Caps With Big Return Potential
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What is the Hang Seng index?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Insider Selling Explained: Can it Inform Your Investing Choices?
- MarketBeat Week in Review – 10/14 – 10/18
Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com for the latest 13F filings and insider trades for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report).
Receive News & Ratings for Madrigal Pharmaceuticals Daily – Enter your email below to get a summary of the latest news and ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
`
